DANIEL SPURLOCK: Open Payments
NPI 1013957257 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$484 in 22 payments from 13 companies in 2025. Trend: 2023 $1,182 · 2024 $1,072 · 2025 $484
Food & beverage: $484
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $83 |
| Neurocrine BioSciences, Inc. | 3 | $72 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| JAZZ PHARMACEUTICALS INC. | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| ABBVIE INC. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: ARISTADA, INGREZZA, AUSTEDO XR, Auvelity, Jornay PM, XYWAV, FANAPT, REXULTI.
Industry payments across MO — which companies pay providers there.
